These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 208124)

  • 1. Lack of correlation between antiinflammatory activity and inhibition of 3',5'-Cyclic AMP phosphodiesterase activity in a series of antiinflammatory agents.
    García-Rafanell J; Sánchez MS; Rimbau V; Forn J
    Rev Esp Fisiol; 1978 Mar; 34(1):55-9. PubMed ID: 208124
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of 3',5'-cyclic AMP phosphodiesterase with anti-inflammatory agents.
    Stefanovich V
    Res Commun Chem Pathol Pharmacol; 1974 Mar; 7(3):573-82. PubMed ID: 4363357
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of 3',5'-cyclic AMP phosphodiesterase by acid mucopolysaccharides and sulfopolysaccharides.
    Stefanovich V
    Res Commun Chem Pathol Pharmacol; 1974 Mar; 7(3):557-72. PubMed ID: 4363356
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclic AMP phosphodiesterase inhibition by coumarins and furanocoumarins.
    Sardari S; Nishibe S; Horita K; Nikaido T; Daneshtalab M
    Pharmazie; 1999 Jul; 54(7):554-6. PubMed ID: 10445247
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on the possible role of cyclic AMP in drug-induced coronary vasodilatation.
    Pöch G; Kukovetz WR
    Adv Cyclic Nucleotide Res; 1972; 1():195-211. PubMed ID: 4353168
    [No Abstract]   [Full Text] [Related]  

  • 6. Modulators of cyclic AMP systems.
    Hess SM; Chasin M; Free CA; Harris DN
    Adv Biochem Psychopharmacol; 1975; (14):153-67. PubMed ID: 242200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
    Dastidar SG; Rajagopal D; Ray A
    Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Heptaminol effect on the activity of adenylcyclase and phosphodiesterase].
    Antaloczy Z; Wollemann M
    Agressologie; 1973; 14(5):309-12. PubMed ID: 4369580
    [No Abstract]   [Full Text] [Related]  

  • 9. Forskolin, phosphodiesterase inhibitors, and cyclic AMP analogs inhibit proliferation of cultured bovine aortic endothelial cells.
    Leitman DC; Fiscus RR; Murad F
    J Cell Physiol; 1986 May; 127(2):237-43. PubMed ID: 3009497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
    Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
    J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiinflammatory therapy for rheumatoid arthritis?
    Cohen IR; Klareskog L
    Arthritis Rheum; 2008 Jan; 58(1):2-4. PubMed ID: 18163490
    [No Abstract]   [Full Text] [Related]  

  • 12. [Inhibition of cyclic 3',5'-nucleotide phosphodiesterase by glypentide and other oral antidiabetic agents (author's transl)].
    García-Rafanell J; Morell-Mestre J
    Rev Esp Fisiol; 1974 Dec; 30(4):277-81. PubMed ID: 4376253
    [No Abstract]   [Full Text] [Related]  

  • 13. Antiinflammatory activity of two phenylindandione derivatives.
    Rosini S; Trallori L
    Farmaco Sci; 1976 Jun; 31(6):403-11. PubMed ID: 1278360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of the effects of sodium nitroprusside and of isoproterenol by selective phosphodiesterase inhibitors.
    Lorenz KL; Wells JN
    Mol Pharmacol; 1983 Mar; 23(2):424-30. PubMed ID: 6300651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs.
    Harrison SA; Chang ML; Beavo JA
    Circulation; 1986 Mar; 73(3 Pt 2):III109-16. PubMed ID: 3002661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of various cyclic AMP phosphodiesterases by pentifylline and theophylline.
    Stefanovich V; von Pölnitz M; Reiser M
    Arzneimittelforschung; 1974 Nov; 24(11):1747-51. PubMed ID: 4374953
    [No Abstract]   [Full Text] [Related]  

  • 17. The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
    Manallack DT; Hughes RA; Thompson PE
    J Med Chem; 2005 May; 48(10):3449-62. PubMed ID: 15887951
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition in vitro of cyclic 3',5' nucleotide phosphodiesterase activity by drugs.
    Moffat AC; Patterson DA; Curry AS; Owen P
    Eur J Toxicol; 1972; 5(3):160-2. PubMed ID: 4346076
    [No Abstract]   [Full Text] [Related]  

  • 19. Cholinergic inhibition of catecholamine-stimulable cyclic AMP accumulation in murine atria.
    Brown JH
    J Cyclic Nucleotide Res; 1979 Dec; 5(6):423-33. PubMed ID: 231610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases.
    Anaya JM; Espinoza LR
    J Rheumatol; 1995 Apr; 22(4):595-9. PubMed ID: 7791149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.